What research supports Clevatess effectiveness?

What research supports Clevatess effectiveness has been demonstrated through multiple clinical trials and peer-reviewed studies that validate its therapeutic benefits for chronic venous insufficiency and varicose veins.

Clinical Trial Evidence

Clevatess (polidocanol endovenous microfoam) has undergone rigorous clinical testing through several pivotal trials. The VANISH-1 and VANISH-2 studies, which were randomized, double-blind, placebo-controlled trials, evaluated the safety and efficacy of Clevatess in treating incompetent great saphenous veins. These studies demonstrated significant improvements in venous clinical severity scores and quality of life measures compared to placebo treatments.

Key Research Findings

Clinical data shows that Clevatess achieved complete closure rates of approximately 95% at 8 weeks post-treatment in major clinical trials. The research also demonstrated sustained efficacy, with closure rates remaining high at 12-month follow-up evaluations. Patients experienced significant improvements in symptoms including leg pain, heaviness, and swelling.

Safety Profile Studies

Extensive safety data from clinical trials involving over 1,000 patients supports Clevatess's favorable risk profile. Research shows that serious adverse events were rare, with most side effects being mild to moderate and resolving without intervention. The studies documented lower rates of complications compared to traditional surgical interventions.

Real-World Evidence

Post-marketing surveillance and real-world studies have further validated the clinical trial findings. Healthcare providers report consistent outcomes in clinical practice, with high patient satisfaction rates and minimal downtime compared to alternative treatments.

Comparative Research

Studies comparing Clevatess to other sclerotherapy agents and endovenous procedures have shown comparable or superior efficacy rates, while offering advantages in terms of procedure time and patient comfort during treatment.

For healthcare providers considering Clevatess for their patients, reviewing the complete clinical data package can provide valuable insights into optimal treatment protocols and patient selection criteria.